Core Insights - The report from Zhongkang Digital Technology Co., Ltd. indicates a significant shift in the pharmaceutical industry from "conceptual trials" to "practical implementation" of AI technologies [1] - Zhongkang Technology has established a comprehensive AI service ecosystem covering the entire industry chain, serving 1,685 clients, including 182 pharmaceutical companies and over 51 hospitals [1] Group 1: AI Implementation in Various Sectors - In marketing, Zhongkang Technology has launched the AI For Marketing Lab, marking a transition to a "trust-driven" marketing era, enhancing ROI visualization and maximization [2] - In the medical sector, the company supports over 510 hospitals with its self-developed "Zhuo Mu Niao Medical Model," which provides evidence-based decision-making tools for complex medical diagnoses [2] - The retail pharmacy sector has seen the deployment of AI systems in over 10,993 pharmacies, transforming operational logic and enhancing professional service capabilities [2] Group 2: Consumer Health Management - Zhongkang Technology has developed an AI system for comprehensive health management, utilizing a user base of over 3 million to provide personalized health interventions and risk warnings [3] - The company focuses on chronic disease and critical illness management, offering medication management and rehabilitation guidance while integrating humanistic care and policy interpretation [3][4] Group 3: Unique Data and Model Capabilities - Zhongkang Technology has transitioned from "data services" to "AI decision-making and intelligent services," creating a unique capability that combines data, models, scenarios, and ecosystems [5] - The company has developed specialized AI models, such as the Zhuo Mu Niao Medical Model, trained on extensive medical literature and knowledge graphs, ensuring high accuracy and relevance [5] - Zhongkang Technology possesses a high-quality data system that spans the entire industry chain, providing deep insights into market trends and patient behaviors [6] Group 4: Industry Challenges and Future Outlook - The pharmaceutical industry is entering a phase of "refined operations," where AI is becoming a fundamental capability rather than a mere vision, addressing challenges like normalized procurement and compliance pressures [7] - Zhongkang Technology aims to establish a "central operating system" for the health industry, integrating the entire value chain and covering all lifecycle application scenarios from prevention to management [7]

Core Insights - The company has made significant progress in the commercialization of AI large models and intelligent agents, covering various sectors including marketing, healthcare, pharmacies, and consumer management, thereby reaching a comprehensive health industry cooperation network [1] Group 1: Marketing - The company has launched the "AI Marketing Laboratory" and introduced the "Tiangong No.1 Commercial Intelligent Agent," providing "+AI" digital solutions to 182 pharmaceutical companies, enabling rapid response and efficient decision-making in a changing environment [1] Group 2: Healthcare - Utilizing its self-developed "Zhuo Mu Niao Medical Large Model," the company has introduced the intelligent agent "iMDT" for multidisciplinary joint consultations, serving 512 hospitals and empowering over 1,520 clinical doctors in complex medical diagnoses, significantly improving the decision quality of multidisciplinary teams (MDT) [1] Group 3: Pharmacy - The company has launched an intelligent agent for pharmacies, serving over 10,993 pharmacies, and established a matrix of five AI intelligent agents covering operational insights, products, diseases, members, and employees, as well as specialized AI for "individuals, families, diseases, and medications" to empower store operations [1] Group 4: Health Management - The company has created an AI intelligent agent matrix covering "individuals, families, diseases, and medications," accurately reaching over 3 million users, providing personalized health interventions and risk warnings, and constructing a comprehensive management system that includes prevention, screening, and intervention [1] Group 5: Business Transformation - The company has successfully transformed from a data technology service provider to an AI technology service provider, and will continue to optimize its capabilities in "data + models + scenarios + ecosystem" to become the preferred AI service provider in the health industry [2]

Core Insights - The company has made significant progress in the commercialization of AI large models and intelligent agents, covering various sectors in the health industry, including marketing, healthcare, pharmacies, and consumer management [1][2] Group 1: Marketing - The company has launched the "AI Marketing Laboratory" and introduced the "Tian Gong No. 1 Commercial Intelligent Agent," providing "+AI" digital solutions to 182 pharmaceutical companies, enabling rapid response and efficient decision-making in a changing environment [1] Group 2: Healthcare - Utilizing its self-developed "Zhuo Mu Niao Medical Large Model," the company has introduced the intelligent agent "iMDT" for multidisciplinary joint consultations, serving 512 hospitals and empowering over 1,520 clinical doctors in complex medical diagnoses, significantly improving the decision quality of multidisciplinary teams (MDT) [1] Group 3: Pharmacy - The company has launched an intelligent agent for pharmacies, serving over 10,993 pharmacies, and established a matrix of five AI intelligent agents covering operational insights, products, diseases, memberships, and employees, as well as specialized AI for "individuals, families, diseases, and medications" to enhance store operations [1] Group 4: Health Management - The company has created a matrix of AI intelligent agents covering "individuals, families, diseases, and medications," accurately reaching over 3 million users, providing personalized health interventions and risk warnings, and constructing a comprehensive management system that includes prevention, screening, and intervention [1] Group 5: Business Transformation - The company has successfully transformed from a data technology service provider to an AI technology service provider, continuously optimizing its capabilities in "data + models + scenarios + ecosystem" to become the preferred AI service provider in the health industry [2]

Core Insights - Zhongkang Holdings (02361.HK) has made significant progress in the commercialization of AI large models and intelligent agents, covering various sectors including marketing, healthcare, pharmacies, and consumer management [1] Marketing - The company has launched the "AI Marketing Laboratory" and introduced the "Tiangong No. 1 · Commercial Intelligent Agent," providing "+AI" digital solutions to 182 pharmaceutical companies, enabling rapid response and efficient decision-making in a changing environment [1] Healthcare - In the healthcare sector, the company has developed the "Zhuomuniao Medical Large Model" and launched the intelligent agent "iMDT" for multidisciplinary joint consultations, serving 512 hospitals and empowering over 1,520 clinical doctors to enhance the quality of decision-making in complex medical diagnoses [2] Pharmacies - In the pharmacy sector, the company has introduced an intelligent agent that has served over 10,993 pharmacies, utilizing comprehensive industry data to establish a matrix of five AI intelligent agents covering operational insights, products, diseases, members, and employees, as well as specialized AI for "individuals, families, diseases, and medications" to empower store operations [3] Consumer Management - In health management, the company has created a matrix of AI intelligent agents covering "individuals, families, diseases, and medications," accurately reaching over 3 million users, providing personalized health interventions and risk warnings, and constructing a comprehensive management system that includes prevention, screening, and intervention [4]

Core Insights - Zhongkang Technology's Tiangong-1 platform has recently completed the adaptation of the advanced language model DeepSeek-V3.2-Exp, emphasizing a dual strategy of technological independence and ecological openness [1][2] Group 1: Technology and Innovation - The Tiangong-1 platform serves as the AI application capability hub for the health industry, built on the dual-core driving architecture of the self-developed "Zhuomuniao" medical model and the "Tiangong-1" decision-making model [1] - This unique architecture integrates the professionalism of the medical field with the broad applicability of business decision-making, ensuring Tiangong-1's leading position and professional barriers in the complex health industry [1] Group 2: Ecosystem and Product Offering - The intelligent agent ecosystem of Tiangong-1 is designed as a combination of a "supermarket" and a "factory," providing standardized intelligent agent products that cover the entire spectrum of "medicine, pharmacy, patients, and management" for users to quickly address common issues [2] - The platform also offers powerful intelligent agent creation tools, allowing clients to customize their agents based on unique business processes, thereby securing proprietary intelligent agent assets and enabling continuous evolution of core capabilities [2] - The adaptation of excellent third-party models like DeepSeek-V3.2-Exp significantly enriches the "raw materials" library under the "factory" model, allowing enterprises to freely combine and call upon various models based on specific task performance, cost, and efficiency requirements, achieving a synergistic effect of "1+1>2" [2]

Core Insights - Zhongkang Technology has launched the "Tiangong No.1 Health Industry AI Application Capability Hub," marking a new phase in the intelligent transformation of the health industry [1][4] - The "Zhuomuniao Medical Model," the core engine of the hub, has achieved the top ranking in the "Medical Language Understanding" category on the MedBench evaluation platform, showcasing its leading position in the medical AI field [1][2] Company Overview - Zhongkang Technology has been deeply integrated with the pharmaceutical industry for 18 years, combining advanced AI technology to create significant business value and strategic importance for pharmaceutical companies [1][2] AI Model Capabilities - The "Zhuomuniao Medical Model" has a scale of 70 billion parameters, enabling it to deeply analyze vast amounts of medical literature, clinical guidelines, and drug instructions, thus providing precise understanding and key information extraction [2] - The hub offers a comprehensive AI application ecosystem that empowers individuals, facilitates organizational collaboration, and fosters technological innovation [2] Individual Empowerment - The commercial intelligent agent of Tiangong No.1 provides seven professional capabilities, significantly enhancing the efficiency of pharmaceutical professionals, such as reducing the time to generate evidence reports from weeks to minutes, achieving a sevenfold increase in efficiency [2] Organizational Collaboration - The "Enterprise Growth Workbench" addresses the challenges of multi-department collaboration in pharmaceutical companies, featuring over 100 intelligent agents that enhance departmental efficiency across the entire pharmaceutical marketing chain [3] - This model breaks down departmental barriers and fosters competitive growth through a "single-point breakthrough × collaborative evolution" approach [3] Technical Foundation - The intelligent agent center serves as the technical foundation of the hub, driven by both the "Zhuomuniao Medical Model" and the "Tiangong No.1 Decision Model," integrating comprehensive market data and industry experience [3] - The multi-model collaboration capability allows for effective responses to complex medical tasks, ensuring knowledge freshness and decision relevance [3] Industry Impact - The launch of the hub is not just a technological advancement but also a foundational infrastructure for the intelligentization of the health industry, aiming to redefine work methods and decision-making processes [4] - Zhongkang Technology aspires to be a standard setter and connector in the health industry AI application ecosystem, promoting an open, innovative, and win-win environment [4][5]

Core Insights - The MedBench platform has released its latest evaluation results for 2025, highlighting the "Zhuomuniao Medical Model" from Zhongkang Technology, which ranked 2nd overall and 1st in medical language understanding, showcasing its significant advantages in integrating natural language processing with medical expertise [1] Group 1: Model Performance - The "Zhuomuniao Medical Model" is built on nearly two decades of data accumulation and industry insights from Zhongkang Technology, utilizing a high-quality training resource that includes over one million medical documents, guidelines, textbooks, and drug instructions, as well as tens of millions of de-identified clinical data, disease records, and unstructured medical records [1] - The model has a parameter count of 70 billion, and its performance is enhanced through large-scale pre-training and multi-stage instruction fine-tuning, along with advanced techniques such as data cleaning, deduplication, and augmentation [1] Group 2: Application and Impact - The "Zhuomuniao Medical Model" serves as an intelligent engine that spans the entire health service chain, supporting the "Healthcare Full-Scenario Intelligent Body" launched by Zhongkang Technology in March 2025 [1] - This intelligent body is developed using the Tiangong No. 1 and Zhuomuniao medical platforms, integrating high-quality industry data, professional knowledge, and leading model distillation technology to create intelligent solutions for various scenarios including commercial, medical, pharmacy, health management, and research [1] - These intelligent bodies are designed to achieve a business closed-loop characterized by "intelligent decision-making, agile action, and controllable results," thereby enhancing efficiency and service quality in the healthcare industry [1]

Core Insights - Zhongkang Holdings (02361.HK) has launched the "Tiangong No.1 Health Industry AI Application Capability Hub," which aims to transform the "Zhuomuniao Medical Model" into a driving force for the industry, providing tangible business value and strategic significance for pharmaceutical companies [1][2] - The hub is positioned as the foundational infrastructure for the intelligent health industry, aiming to become a unified entry point and standard setter for AI applications in the health sector, connecting the entire pharmaceutical value chain from research and development to production, distribution, and services [1][2] Company Developments - The "Tiangong No.1 Health Industry AI Application Capability Hub" is based on the "Zhuomuniao Medical Model," which ranks first in the "Medical Language Understanding" assessment on the MedBench platform, attributed to its 70 billion parameters that allow for deep analysis of vast amounts of medical literature [2] - The company emphasizes that the AI industry has moved beyond mere technical competition to a new stage where "application defines value," particularly in the health sector, as highlighted by the State Council's recent directive to promote AI in various healthcare applications [2] Future Outlook - Zhongkang Technology plans to continuously enhance the "Tiangong No.1 Health Industry AI Application Capability Hub" and collaborate with industry peers to explore new paths for AI-enabled marketing, aiming for a comprehensive intelligent upgrade of the health industry [2]

Core Insights - Zhongkang Technology has launched the "Tiangong No.1 Health Industry AI Application Capability Hub," marking a new phase in the intelligent transformation of the health industry [1][9] - The "Zhuomuniao Medical Model" achieved the top rank in the "Medical Language Understanding" category on the MedBench evaluation platform, highlighting its leading position in the pharmaceutical AI sector [1][2] Group 1: Technological Leadership - The "Zhuomuniao Medical Model" boasts 70 billion parameters, enabling it to deeply analyze vast amounts of medical literature, thus providing precise understanding and extraction of key information [2] - This model addresses the limitations of general AI in the medical field, establishing a solid foundation for deep applications of AI in the health industry [2] Group 2: Industry Value - The "Tiangong No.1 Health Industry AI Application Capability Hub" integrates 18 years of Zhongkang's pharmaceutical industry data and experience, creating a comprehensive AI application ecosystem [3] - The commercial intelligent agent within the hub enhances individual efficiency, allowing medical professionals to generate evidence reports in minutes, increasing productivity by up to 7 times [3] Group 3: Organizational Collaboration - The "Enterprise Growth Workbench" addresses inter-departmental collaboration challenges by providing over 100 intelligent agents that enhance efficiency across the pharmaceutical marketing chain [5][6] - This model breaks down departmental barriers, fostering competitive growth through collaborative evolution [6] Group 4: Strategic Significance - The hub aims to serve as a foundational infrastructure for the intelligent upgrade of the health industry, connecting all segments from research and development to production and distribution [8] - It seeks to redefine operational methods and decision-making processes in the health industry, promoting a new paradigm of human-machine collaboration [8] - Zhongkang Technology is positioned to become a standard setter and connector in the health industry AI application ecosystem, driving innovation and collaboration [8][9]

Core Viewpoint - The recent policy from the State Council to promote AI in healthcare significantly boosts the AI medical industry, indicating a favorable environment for companies like Zhongkang Holdings [1][10]. Group 1: Company Performance - Zhongkang Holdings reported a revenue of 150 million yuan in the first half of the year, a decrease of 7.3% year-on-year, and a net profit of 24.5 million yuan, down 42.1% year-on-year [3]. - The company is undergoing a strategic "deep squat," focusing on building a comprehensive intelligent system in the healthcare sector, which requires substantial upfront investment [3]. - R&D expenses increased by approximately 14.4% year-on-year, indicating a commitment to enhancing computing infrastructure and expanding high-level R&D talent [3]. Group 2: Market Perception and Valuation - Zhongkang Holdings has a market capitalization of only 1.5 billion HKD and a price-to-sales ratio of 3.4, suggesting significant undervaluation [4]. - The market has not fully recognized the company's deep and forward-looking investments in AI, leading to a discrepancy in expected growth potential [5]. Group 3: AI Integration and Business Model - The company integrates AI into its core operations, providing a one-stop AI-driven solution for various clients in the life sciences sector [5]. - Zhongkang has developed advanced AI models and platforms, including the Zhuomuniao medical model and Tian Gong No.1 commercial model, which enhance its service offerings [5][6]. Group 4: Ecosystem and Growth Potential - The company is building a robust "ecological flywheel" effect, where data, models, scenarios, and users interact to create significant value [6][9]. - The accumulation of healthcare data through partnerships allows Zhongkang to train precise AI models, enhancing service efficiency and attracting more users [7]. - The potential for exponential growth exists as the ecological flywheel accelerates, driven by the increasing demand for intelligent solutions in the healthcare sector [9][10].